These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 25934575)

  • 1. Hydroxylation and N-dechloroethylation of Ifosfamide and deuterated Ifosfamide by the human cytochrome p450s and their commonly occurring polymorphisms.
    Calinski DM; Zhang H; Ludeman S; Dolan ME; Hollenberg PF
    Drug Metab Dispos; 2015 Jul; 43(7):1084-90. PubMed ID: 25934575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide.
    Huang Z; Roy P; Waxman DJ
    Biochem Pharmacol; 2000 Apr; 59(8):961-72. PubMed ID: 10692561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes.
    Granvil CP; Madan A; Sharkawi M; Parkinson A; Wainer IW
    Drug Metab Dispos; 1999 Apr; 27(4):533-41. PubMed ID: 10101149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation.
    McCune JS; Risler LJ; Phillips BR; Thummel KE; Blough D; Shen DD
    Drug Metab Dispos; 2005 Jul; 33(7):1074-81. PubMed ID: 15821045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of cytochrome P450 in oxazaphosphorine metabolism. Deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450.
    Yu L; Waxman DJ
    Drug Metab Dispos; 1996 Nov; 24(11):1254-62. PubMed ID: 8937861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes.
    Schmidt R; Baumann F; Knüpfer H; Brauckhoff M; Horn LC; Schönfelder M; Köhler U; Preiss R
    Br J Cancer; 2004 Feb; 90(4):911-6. PubMed ID: 14970873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation.
    Chang TK; Yu L; Goldstein JA; Waxman DJ
    Pharmacogenetics; 1997 Jun; 7(3):211-21. PubMed ID: 9241661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants.
    Vredenburg G; den Braver-Sewradj S; van Vugt-Lussenburg BM; Vermeulen NP; Commandeur JN; Vos JC
    Toxicol Lett; 2015 Jan; 232(1):182-92. PubMed ID: 25448283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereoselective metabolism of ifosfamide by human P-450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer.
    Roy P; Tretyakov O; Wright J; Waxman DJ
    Drug Metab Dispos; 1999 Nov; 27(11):1309-18. PubMed ID: 10534317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide.
    May-Manke A; Kroemer H; Hempel G; Bohnenstengel F; Hohenlöchter B; Blaschke G; Boos J
    Cancer Chemother Pharmacol; 1999; 44(4):327-34. PubMed ID: 10447581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender difference in ifosfamide metabolism by human liver microsomes.
    Schmidt R; Baumann F; Hanschmann H; Geissler F; Preiss R
    Eur J Drug Metab Pharmacokinet; 2001; 26(3):193-200. PubMed ID: 11695720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereoselectivity in metabolism of ifosfamide by CYP3A4 and CYP2B6.
    Lu H; Wang JJ; Chan KK; Philip PA
    Xenobiotica; 2006 May; 36(5):367-85. PubMed ID: 16854777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide.
    Walker D; Flinois JP; Monkman SC; Beloc C; Boddy AV; Cholerton S; Daly AK; Lind MJ; Pearson AD; Beaune PH
    Biochem Pharmacol; 1994 Mar; 47(7):1157-63. PubMed ID: 8161344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines.
    Chang TK; Yu L; Maurel P; Waxman DJ
    Cancer Res; 1997 May; 57(10):1946-54. PubMed ID: 9157990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics.
    Chen CS; Lin JT; Goss KA; He YA; Halpert JR; Waxman DJ
    Mol Pharmacol; 2004 May; 65(5):1278-85. PubMed ID: 15102956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles.
    Roy P; Yu LJ; Crespi CL; Waxman DJ
    Drug Metab Dispos; 1999 Jun; 27(6):655-66. PubMed ID: 10348794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of 4-hydroxylation of ifosfamide in human liver microsomes using the estimation of free and protein-bound acrolein and codetermination of keto- and carboxyifosfamide.
    Preiss R; Schmidt R; Baumann F; Hanschmann H; Hauss J; Geissler F; Pahlig H; Ratzewiss B
    J Cancer Res Clin Oncol; 2002 Jul; 128(7):385-92. PubMed ID: 12136253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variability in human drug metabolizing cytochrome P450 CYP2C9, CYP2C19 and CYP3A5 activities caused by genetic variations in cytochrome P450 oxidoreductase.
    Velazquez MNR; Parween S; Udhane SS; Pandey AV
    Biochem Biophys Res Commun; 2019 Jul; 515(1):133-138. PubMed ID: 31128914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes.
    Chang TK; Weber GF; Crespi CL; Waxman DJ
    Cancer Res; 1993 Dec; 53(23):5629-37. PubMed ID: 8242617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of anthocyanidins and anthocyanins on the expression and catalytic activities of CYP2A6, CYP2B6, CYP2C9, and CYP3A4 in primary human hepatocytes and human liver microsomes.
    Srovnalova A; Svecarova M; Zapletalova MK; Anzenbacher P; Bachleda P; Anzenbacherova E; Dvorak Z
    J Agric Food Chem; 2014 Jan; 62(3):789-97. PubMed ID: 24387788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.